Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
Article
Google Scholar
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:1434–43.
Article
CAS
Google Scholar
Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 8):viii75–82.
Google Scholar
Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115:429–30.
Article
Google Scholar
Severson TM, Zwart W. A review of estrogen receptor/androgen receptor genomics in male breast cancer. Endocr Relat Cancer. 2017;24:R27–34.
Article
Google Scholar
Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol. 2013;26:87–94.
Article
CAS
Google Scholar
Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232–9.
Article
Google Scholar
White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011;13:219.
Article
Google Scholar
Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131–40.
Article
CAS
Google Scholar
Chia K, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Curr Oncol Rep. 2015;17:4.
Article
Google Scholar
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast Cancer program. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:405–17.
CAS
Google Scholar
Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37:246–51.
Article
CAS
Google Scholar
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer--a case-control study from Scandinavia. Acta Oncol. 2001;40:467–71.
Article
CAS
Google Scholar
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735–42.
Article
CAS
Google Scholar
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114–22.
Article
Google Scholar
Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18:179.
Article
Google Scholar
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–9.
Article
CAS
Google Scholar
Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, et al. The prognostic significance of combined androgen receptor, E-cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget. 2017;8:76974–86.
PubMed
PubMed Central
Google Scholar
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401–6.
Article
CAS
Google Scholar
Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.
Article
CAS
Google Scholar
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457–71.
Article
CAS
Google Scholar
Guo W, Keener AL, Jing Y, Cai L, Ai J, Zhang J, et al. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. Prostate. 2015;75:976–87.
Article
CAS
Google Scholar
Union for International Cancer Control-TNM classification, 8th edition. 2016.
Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10:471–9.
Article
Google Scholar
Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010;12(Suppl 2):S2.
Article
Google Scholar
Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, et al. EORTC 10941: a phase II study of liarozole in postmenopausal patients with ‘chemotherapy-resistant’ or ‘potentially hormone sensitive’ metastatic breast cancer. Breast Cancer Res Treat. 2000;60:181–8.
Article
CAS
Google Scholar
Sawaki M, Wada M, Sato Y, Mizuno Y, Kobayashi H, Yokoi K, et al. High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: a multicenter phase II study. Oncol Lett. 2012;3:61–5.
Article
CAS
Google Scholar
Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, et al. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer. 2010;17:254–60.
Article
Google Scholar
Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial. Breast Cancer Res Treat. 1993;25:57–63.
Article
CAS
Google Scholar
Binkhorst L, Mathijssen RHJ, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015;41:289–99.
Article
CAS
Google Scholar
Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer. 2013;13:503.
Article
Google Scholar
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami KI, Okumura Y, Tomita S, et al. Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. Br J Cancer. 2013;109:1537–42.
Article
CAS
Google Scholar
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–59.
Article
CAS
Google Scholar
Takuwa H, Saji S, Takada M, Takahara S, Yamauchi, A. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: a retrospective study. Breast Dis 2018; Epub ahead of print. doi:https://doi.org/10.3233/BD-170307.
Gunnarsson PO, Forshell GP. Clinical pharmacokinetics of estramustine phosphate. Urology. 1984;23:22–7.
Article
CAS
Google Scholar
Imamov O, Lopatkin NA, Gustafsson JA. Estrogen receptor beta in prostate cancer. N Engl J Med. 2004;351:2773–4.
Article
Google Scholar
Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol Cancer Res. 2009;7:129–41.
Article
CAS
Google Scholar
Gui B, Hsieh CL, Kantoff PW, Kibel AS, Jia L. Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS One. 2017;12:e0184166.
Article
Google Scholar